[1] |
XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue.
285 cases of adverse drug reaction related to new antineoplastic drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
|
[2] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[3] |
MENG Kangkang, LIU Saiyue.
After-marketing safety of coenzyme Q10 for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
|
[4] |
CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin.
Analysis of reports of allergic shock in Chongqing between 2015 and 2020
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
|
[5] |
WEI Anhua, QI Jianjun, WANG Lu, ZENG Lu, GONG Xuepeng, JIANG Ying.
Adverse drug reaction/ event caused by oral antidiabetic drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1415-1420.
|
[6] |
PENG Jing, TUO Yali, LI Qiaoling, ZHOU Rong, LI Xinlin, PENG Hui.
Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1264-1268.
|
[7] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[8] |
ZHANG Luxin, MENG Lu, ZHANG Hong.
Analysis of 327 reports of new adverse drug reactions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1159-1162.
|
[9] |
YAO Yu, LI Yuanyuan, WEI Xu, XIE Yanming, WANG Zhifei, GAO Minghui.
Influencing factors of suspected allergic reactions related to cervus and cucumis polypeptide for injection in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 740-743.
|
[10] |
YI Yan, TIAN Jingzhuo, LI Chunying, ZHAO Yong, LIANG Aihua.
Pesudoallergic reactions during post-marketing non-clinical safety reevaluation of traditional Chinese medicine injections
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 185-188.
|
[11] |
LIU Chun, WANG Jucai, HUANG Yuchang, YE Xiaoqing, ZHAO Yingshu, ZHAN Meimei, WANG Chen.
Allergic test of azithromycin for injection in guinea pigs in non-clinical safety evaluation
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1161-1164.
|
[12] |
WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong.
Factors related to ADR/ADE of albumin bound paclitaxel
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
|
[13] |
XU Xianxing, YANG Jingwen, MIAO Huiqing.
Potential Risks of Salviae Miltiorrhizae and Ligustrazine Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 575-578.
|
[14] |
FU Hong, RONG Youhe.
One Case of Severe Adverse Drug Reactions Induced by rt-PA and Literature Analysis
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1198-1200.
|
[15] |
QIN Xueying, SUN Linxi, XIE Yanming, LYU Jian, ZHANG Cheng, XIE Yuting, GUO Peng.
Influencing Factors of Suspected Allergic Reactions Caused by Yinzhihuang Granules in the Real World
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 936-939.
|